-

Thermo Fisher Scientific demonstrates commitment to transplant patients and collaboration at ASHI 2022

Multiple abstracts, three sponsored sessions and patient advocacy campaign debut top company contribution to conference that draws attendees from around the world

LAS VEGAS--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will demonstrate the benefits of collaborating to advance the science of transplantation and connecting breakthroughs to patients this week at the 48th Annual Meeting of the American Society for Histocompatibility & Immunogenetics (ASHI) Conference in Las Vegas. The innovations will be featured in a number of abstracts, three sponsored sessions and the launch of a new patient advocacy campaign, which can be seen at booth #100.

Among the innovations to be showcased by Thermo Fisher’s transplant diagnostics business are two separate multi-center studies at European, South American, Asian and United States transplant centers that were conducted to evaluate the One Lambda AllType FASTplex assay—a unique and easy-to-use next-generation sequencing assay for human leukocyte antigen (HLA) typing—in clinical settings. High-resolution genotyping of the HLA locus is key to ensuring the best donor–recipient match. The studies demonstrated robust performance and accurate typing results.

The leading maker of transplant diagnostics will also debut its Counting on you patient advocacy campaign, which celebrates the lives of transplant recipients by “counting” their extraordinary and everyday milestones post-transplant. The campaign also gives the recipients a platform to say thank you to their donors and the individuals whose work enables the lifesaving miracle of transplantation. The campaign represents the evolution of the company’s transplant patient advocacy efforts. Earlier this year, One Lambda, a Thermo Fisher Scientific brand, sponsored the Letters of Hope docuseries, which recently won an award for positive storylines related to organ transplantation.

“The work being done in transplant laboratories around the globe is the reason we are able to move the science of transplantation forward,” said Nicole Brockway, president, transplant diagnostics, Thermo Fisher Scientific. “We’re proud to partner with our customers to deliver the workflow of the future to help improve the quality of life for transplant recipients. As our new patient advocacy campaign vividly affirms, transplant recipients make the world a better place simply by being a part of it.”

Other One Lambda–branded technologies to be highlighted at the conference include TypeStream Visual NGS Analysis Software (TSV) and a unique, highly efficient, rapid, and accurate method for typing noncoding sequences that have been shown to be important to transplant patient outcomes.

See Letters of Hope and the Counting on you stories at onelambda.com/patient-advocacy

Sponsored sessions

Pre-ASHI Workshop
Monday, October 24, 2022
1:00–4:00 p.m. PT
Palace Meeting Room #3

User Group Meeting: Increasing Confidence in Your Virtual Crossmatching
Tuesday, October 25, 2022
12:15–2:05 p.m. PT
Jubilee Tower (Jubilee 1)

User Group Meeting: Evolving Perspectives on Epitopes: Debating the Emerging Research
Wednesday, October 26, 2022
11:45–1:35 p.m. PT
Jubilee Tower (Jubilee 1)

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:
Deborah Bright
Phone: 760-271-4239
E-mail: deborah.bright@thermofisher.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media:
Deborah Bright
Phone: 760-271-4239
E-mail: deborah.bright@thermofisher.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom